Product Description: Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC)[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Karwa R, et al. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23./[2]Cowen LE, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2818-23.
CAS Number: 762260-74-2
Molecular Weight: N/A
Research Area: Infection
Solubility: H2O
Target: Fungal